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Abstract
Repeated administrations of NMDA receptor antagonists induce behavioural changes which resemble the
symptoms of schizophrenia in animals. ERK and GSK-3b associated signalling pathways have been
implicated in the pathogenesis of psychosis and in the action mechanisms of various psychotropic agents.
Here, we observed the phosphorylations of ERK and GSK-3b and related molecules in the rat frontal
cortex after repeated intraperitoneal injections of MK-801, over periods of 1, 5, and 10 d. Repeated treat-
ment with 0.5, 1, and 2 mg/kgMK-801 increased the phosphorylation levels of the MEK-ERK-p90RSK and
Akt-GSK-3b pathways and concomitantly and significantly increased CREB phosphorylation in the rat
frontal cortex. However, single MK-801 treatment did not induce these significant changes. In addition,
the immunoreactivities of HSP72, Bax, and PARP were not altered, which suggests that neuronal damage
may not occur in the rat frontal cortex in response to chronic MK-801 treatment. These findings suggest
that chronic exposure to MK-801 may induce pro-survival and anti-apoptotic activity without significant
neuronal damage in the rat frontal cortex. Moreover, this adaptive change might be associated with the
psychotomimetic action of MK-801.
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Introduction
MK-801 is a non-competitive, selective NMDA recep-
tor antagonist, and has been demonstrated to induce
psychotomimetic behaviour in rodents. The single
administration of an NMDA receptor antagonist was
found to result in acute psychotomimetic behavioural
effects, including locomotor activity and stereotypy
(Andine et al., 1995). On the other hand, prolonged
treatment of rats with NMDA receptor antagonists
were found to induce behavioural effects, which are
consistent with the cognitive deficits and negative
symptoms of schizophrenia, and sensitized psychoto-
mimetic behaviour. Therefore, the chronic exposure of
rats to NMDA receptor antagonist may provide a
more appropriate animal model than acute exposure
since it results in adaptive responses that model in
certain aspects of the schizophrenic state in humans
(Jentsch and Roth, 1999).
NMDA receptor antagonists induce functional
alterations in the brain, and the NMDA receptor
hypofunctional state induces aberrations in the
GABAergic, serotonergic, adrenergic, and dopamin-
ergic neurotransmission systems (Farber, 2003), and
chronic exposure to phencyclidine (PCP) has been
reported to generate compensatory hyperfunctional
NMDA receptors (Yu et al., 2002). Blood flow, dopa-
mine neurotransmission, and glucose utilization,
which together represent brain functional activity, can
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also be influenced by NMDA receptor antagonist
treatment (Jentsch and Roth, 1999). On the other hand,
NMDA receptor antagonists also affect the fates of
neuronal cells. Although many studies have indicated
that neuronal damage occurs in response to NMDA
receptor antagonists (Carter et al., 2004 ; Sharp et al.,
1991 ; Tomitaka et al., 2000), NMDA receptor antag-
onists can also protect neurons from various stimuli
including excitotoxicity (Molinuevo et al., 2005;
Thomas and Kuhn, 2005). Moreover, these functional
and structural changes induced by NMDA receptor
antagonists can result from the actions of intracellular
signalling pathways. However, the action mechanisms
of NMDA receptor antagonists on intracellular sig-
nalling pathways in vivo, altering the activity of neural
system has yet to be clarified.
Although the intracellular mechanisms underlying
the psychotomimetic effects of NMDA antagonists
remain poorly understood, the Ras-MAPK kinase
(MEK)-MAPK and the PI3 kinase-Akt-GSK-3b signal-
ling pathways have been suggested to be the primary
signalling pathways exploited by NMDA receptors
(Grewal et al., 1999 ; Zhu et al., 2005). It has been
reported that ERK1/2 and Akt can be activated by
NMDA receptor activation, and that MK-801 treat-
ment reduces the phosphorylation levels of ERK1/2
and Akt in cortical neuronal cultures (Bading and
Greenberg, 1991; Chandler et al., 2001; Sutton and
Chandler, 2002).
The Ras-MAPK kinase (MEK)-MAPK and the PI3
kinase-Akt-GSK-3b signalling pathways have been
implicated in both the pathogenesis and in the thera-
peutic mechanisms associated with the treatment
of psychosis. Reduced protein levels and GSK-3b
activities in the frontal cortex (Beasley et al., 2001;
Kozlovsky et al., 2001), and increased ERK2 protein
and mRNA levels in the thalamus (Kyosseva, 2004)
have been revealed by post-mortem studies of
schizophrenia. The pathway involving GSK-3b was
also suggested to be a common signalling pathway
on which various psychotomimetic agents act
(Svenningsson et al., 2003). Moreover, antipsychotics
such as clozapine and olanzapine, and electro-
convulsive shock treatment (ECS) have been shown to
increase the phosphorylation of GSK-3b and ERK in
both cell lines and in rat brains (Browning et al., 2005;
Kang et al., 2004 ; Lu et al., 2004 ; Roh et al., 2003).
Recently, our group reported that a single treat-
ment with MK-801 results in acute dose-dependent
phosphorylation changes in the Akt-GSK-3b and
c-Raf-MEK-ERK signalling pathways in the rat frontal
cortex, and associated these phosphorylation changes
with the behavioural changes induced by MK-801
(Ahn et al., 2005a,b). Although the evaluation of
possible changes in these pathways after repeated
applications of MK-801, will provide necessary infor-
mation regarding the intracellular mechanisms
underlying the psychotomimetic effects exerted by
MK-801, it cannot be expanded from the results of
acute experiments alone (Jentsch and Roth, 1999).
In this study, we observed changes in GSK-3b and
ERK1/2 related molecules in the rat frontal cortex
after repeated intraperitoneal (i.p.) injections of 0.5, 1,
and 2 mg/kg MK-801. Changes in these pathways can
be associated with alterations in the fates of neuronal
cells and with altered brain functional activities
induced by repeated MK-801 treatment. Here, we
found that chronic MK-801 treatment up-regulates the
Akt-GSK-3b and MEK-ERK-p90RSK pathways and
concurrently activates CREB in the rat frontal cortex.
These findings suggest that the pro-survival activity of
signalling pathways is enhanced by chronic exposure
to MK-801.
Materials and Methods
Animals and drug treatment
Male Sprague–Dawley rats (150–200 g) were separ-
ated into groups (described below), and maintained
on a 12-h light–dark cycle with food and water
available ad libitum. All animal treatments were con-
sistent with the protocols described in the NIH Guide
for the Care and Use of Laboratory Animals. MK-801
(Tocris, St. Louis, MO, USA), dissolved in normal
saline was administered by i.p. injection to treated
animals, whereas saline-treated control (Vehicle)
animals received injections containing equivalent
volumes of normal saline. Sham (Normal control)
animals were treated in precisely the same way but
were not injected intraperitoneally.
MK-801 dosages were decided upon based on our
previous acute experimental findings (Ahn et al.,
2005a,b). In our previous acute experiments, MK-801
dosages of 0.5, 1, and 2 mg/kg induce different levels
of psychotomimetic behavioural change. In the frontal
cortex, MK-801 at 0.5 mg/kg increased Akt-GSK-3b
phosphorylation, but reduced MEK1/2-ERK1/2
phosphorylation at 1 h after a single MK-801 injection.
MK-801 at 1 mg/kg also induced the same pattern of
phosphorylation changes, with maximal Akt-GSK-3b
phosphorylation. However, 2 mg/kgMK-801 elevated
the phosphorylation levels of Akt-GSK-3b and MEK1/
2-ERK1/2. Therefore, we attempted to determine the
effects of 0.5, 1, and 2 mg/kg MK-801 on GSK-3b- and
ERK-related molecules in the rat frontal cortex after
repeated MK-801 treatment.
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Rats were given a single injection (of MK-801 or
normal saline) or repeated injections (of MK-801 or
normal saline) for 5 or 10 consecutive days (one injec-
tion per day at the same time of the day) [abbreviation:
1r (single injection), 5r, and 10r (repeated injec-
tions)]. Animals were sacrificed by decapitation 24 h
after final injections to examine chronic changes and
rat frontal cortices were excised and immediately (<2
min) frozen in liquid nitrogen to exclude the possible
confounding effect of GSK-3 phosphorylation changes
(Li et al., 2005) until required for analysis.
Western blot analysis
Whole extracts of frontal cortex were used for Western
blot analysis. Frontal cortices were immediately
homogenized in RIPA(+) (0.1% SDS, 1.0% Triton,
1.0% deoxycholate, 0.1% NaN3 in PBS) containing
5 mm DTT, 1% protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, USA), and 1 mm PMSF
(Sigma-Aldrich) for 15 min at 4 xC. Protein concen-
trations were quantified using a Bio-Rad protein assay
kit (Bio-Rad Laboratories, Hercules, CA, USA). Homo-
genates were then centrifuged, and supernatants were
boiled in Laemmli’s sample buffer. Equal quantities of
proteins were separated by SDS–polyacrylamide gel
electrophoresis (SDS–PAGE), and the resulting gels
were then either stained with Coomassie Blue, or
transferred to nitrocellulose membranes (Bio-Rad
Laboratories). For Western blotting, membranes were
blocked with 5% skim milk in TBS-T (0.1% Tween-20
in TBS) for 1 h at room temperature, on a shaker and
then incubated with anti-actin (Sigma-Aldrich), anti-
phospho-GSK-3 (Tyr216 of GSK-3b/Tyr297 of GSK-
3a) (Upstate Biotechnology, Lake Placid, NY, USA),
anti-HSP72 (C92, StressGen, Victoria, BC, Canada),
anti-GSK-3, anti-CREB, anti-ERK1/2, anti-MEK1/2,
anti-c-Raf, anti-p90RSK, anti-Bax (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), anti-PARPP,
anti-phospho-GSK-3b (Ser9), anti-phospho-GSK-3a
(Ser21), anti-phospho-Akt (Ser473), anti-phospho-Akt
(Thr308), anti-phospho-CREB (Ser133), anti-phospho-
ERK1/2 (Thr202/Tyr204), anti-phospho-MEK1/2
(Ser217/Ser221), anti-phospho-c-Raf (Ser259), anti-
phospho-c-Raf (Ser338), and anti-phospho-p90RSK
(Ser380) (Cell Signaling Technology, Beverly, MA,
USA) specific antibodies, at 1 :1000–3000 dilutions at
4 xC overnight. The membranes were then incubated
with horseradish peroxidase-conjugated anti-rabbit
IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
and signals were detected using an ECL system
(Pierce, Rockford, IL, USA). Film exposures were
adjusted as determined by preliminary experiments.
Immunohistochemistry
Different animals were used for immunohistohemistry
from the animals used for Western blot analysis.
However, they were treated in the same way except
the methods of analysis. Rats received injections
(1 mg/kg MK-801 i.p.), and were then transcardially
perfused with 200 ml saline solution, followed by
500 ml of 4% paraformaldehyde (Sigma-Aldrich) in
0.01 M PBS (pH 7.4). Brains were then immediately
removed and cryoprotected in 20% sucrose solution at
4 xC for 24 h. Cryoprotected brains were sectioned at
20 mm on a freezing microtome (Leitz, Wetzlar,
Germany). In order to perform immunohisto-
chemistry, we used the FR1 and FR2 areas of the
frontal cortex (Paxinos and Watson, 1998), and sec-
tions were incubated with phospho-Thr202/Tyr204-
ERK1/2 and phospho-Ser9GSK-3b (Cell Signaling
Technology) at a 1 :10000 dilution for 7 d at 4 xC and
then incubated with FITC-488 conjugated secondary
antibody (1 :200 ; Molecular Probes, Eugene, Oregon,
USA) for 2 h at room temperature. The sections were
then fluorescence-labelled, and were also counter-
stained with DAPI (0.4 ml/ml ; Sigma-Aldrich), and
then examined by fluorescence microscopy.
Statistical analysis
Three animals were assigned to each treatment group
[Sham, vehicle, 0.5, 1, and 2 mg/kg MK-801, single/
repeated (for 1, 5 and 10 d)]. Results are expressed as
relative optical densities, and are presented as
mean¡S.E. The mean relative optical densities of each
immunoreactivity of molecules were compared with
the vehicle control value of each group using analysis
of variance (ANOVA) (Figures 1, 2, 4, and 5). In order
to determine dose dependency effects, data were
analysed using two-way ANOVA followed by the
Student–Newman–Keuls post-hoc test with respect to
doses of MK-801 and treatment length (Figure 4).
p values of <0.05 were considered statistically sig-
nificant. All tests were performed using SPSS 12.0 for
Windows (SPSS Inc., Chicago, IL, USA).
Results
Repeated treatment with 1 mg/kg MK-801 for 5 d was
found to increase the immunoreactivities of p-Ser473-
Akt and p-Ser9-GSK-3b in the rat frontal cortex at 24 h
after the final injection. After 10 d of repeated injec-
tions, the phosphorylations of these molecules were
also increased in the rat frontal cortex again at 24 h
after the final injection. However, p-Ser473-Akt and
p-Ser9-GSK-3b were unchanged 24 h after a single
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injection of 1 mg/kg MK-801. The p-Ser473-Akt
immunoreactivity levels in the 5-d and 10-d treatment
groups were 248% and 254% of those of the corre-
sponding vehicle controls (F=50.14, d.f.=1, p<0.01
and F=181.05, d.f.=1, p<0.01). The p-Ser9-GSK-3b
immunoreactivity levels of the 5-d and 10-d treat-
ment groups were 305% and 277% of the vehicle
control values (F=197.66, d.f.=1, p<0.01 and F=
107.03, d.f.=1, p<0.01). The immunoreactivities of
total Akt, GSK-3b, and GSK-3a were unchanged after
repeated injections with 1 mg/kg MK-801 and the
immunoreactivities of p-Thr308-Akt, p-Ser21-GSK-3a,
p-Tyr216-GSK-3b, and p-Tyr297-GSK-3a were not af-




were increased in frontal cortices in the 5-d and 10-d
treatment groups (1 mg/kg MK-801), but were
unchanged in the 1-d treatment group (1 mg/kg
MK-801). p-Ser217/Ser221-MEK immunoreactivity
levels in the 5-d and 10-d treatment groups were
244% and 284% of the vehicle control levels
(F=17.346, d.f.=1, p=0.01 and F=105.88, d.f.=1,
p<0.01). Immunoreactivity levels of p-Thr202/
Tyr204-ERK1/2 in the 5-d and 10-d treatment groups
were 259% and 232% of the vehicle control levels,
respectively (F=130.74, d.f.=1, p<0.01 and F=30.70,
d.f.=1, p<0.01). p-Ser380-p90RSK immunoreactivity
levels in the 5-d and 10-d treatment groups were 224%
and 264% of that of the vehicle controls (F=
53.41, d.f.=1, p<0.01 and F=92.42, d.f.=1, p<0.01).
The immunoreactivities of total MEK, ERK, and
p90RSK were unchanged after repeated 1 mg/kg
MK-801 treatment in any group, and the phosphoryl-
ations of c-Raf on Ser259 and Ser338 remained
unchanged in the 5-d and 10-d treatment groups
(Figure 2).
Phospho-Ser133-CREB immunoreactivity was also
elevated in the frontal cortex in the 5-d and 10-d
treatment groups (1 mg/kg MK-801), but was
unchanged in the 1-d treatment group (1 mg/kg
MK-801). Immunoreactivity levels of p-Ser133-CREB
in the 5-d and 10-d treatment groups were 267%
and 243% of the vehicle control values, respectively
(F=69.21, d.f.=1, p<0.01 and F=128.66, d.f.=1,
p<0.01). However, total CREB immunoreactivity was
unchanged after repeated injection with 1 mg/kg of
MK-801 (Figure 2).
In order to confirm the immunoblot findings,
immunohistochemical analysis was conducted on
rat frontal cortical tissues. Increased p-Ser9-GSK-3b
and p-Thr202/Tyr204-ERK1/2 immunoreactivities
were observed in the 10-d treatment group (1 mg/kg
MK-801). Based on cell morphology observations,
neurons in the frontal cortex were observed to contain
both p-Ser9-GSK-3b and p-Thr202/Tyr204-ERK1/2.
The number of neuronal cells densely stained for
p-Ser9-GSK-3b and p-Thr202/Tyr204-ERK1/2 were
higher in the 10-d treatment group than in the vehicle
control group (Figure 3).
As mentioned previously, 0.5, 1, and 2 mg/kg
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Figure 1. Increased immunoreactivity of p-Ser473-Akt and
p-Ser9-GSK-3b induced by repeated treatments with
1 mg/kg MK-801 in the rat frontal cortex. (a) Immunoblots
of rat frontal cortex after repeated treatments with MK-801
(1 mg/kg) for 1, 5, or 10 d. The immunoreactivities of
p-Ser473-Akt and p-Ser9-GSK-3b were increased vs. the
vehicle controls in the 5-d and 10-d treatment groups. The
immunoreactivities of Akt, p-Thr308-Akt, GSK-3a, GSK-3b,
p-Tyr216-GSK-3b, and p-Tyr297-GSK-3a were similar to
those of the vehicle controls after 1-d, 5-d, and 10-d MK-801
treatment. (b) Comparison of immunoblot and densitometry
results. Mean optical densities (ODs) of p-Ser473-Akt and
p-Ser9-GSK-3b were significantly elevated vs. vehicle control
in the 5-d and 10-d MK-801 treatment groups. Data are
expressed as relative ODs, and represent means¡S.E. Relative
ODs are quoted as percentages vs. the ODs of the sham
(normal untreated controls). S and V indicate the normal
and vehicle controls respectively. The asterisks (*) denote
significant differences between the OD of the MK-801
treatment group and the OD of the vehicle controls (p<0.05).
362 M. S. Seo et al.
the phosphorylations of ERK- and GSK-3b-related
molecules at 1 h after intraperitoneal injection of
MK-801. In order to confirm this dose-dependency in
the chronic experiments, we also examined the
immunoreactivities of p-Ser473-Akt, p-Ser9-GSK-3b,
p-Ser217/Ser221-MEK1/2, p-Thr202/Tyr204-ERK1/2,
p-Ser380-p90RSK, and p-Ser133-CREB in the rat
frontal cortex after repeated injections with 0.5 and
(a) 1×

















































































































S 1× 5× 10×S 1× 5× 10×
Sham Vehicle MK-801
Figure 2. Increased immunoreactivities of p-Ser217/Ser221-
MEK1/2, p-Thr202/Tyr204-ERK1/2, p-Ser380-p90RSK, and
p-Ser133-CREB induced by repeated treatment with 1 mg/kg
MK-801 in the rat frontal cortex. (a) Immunoblots of rat
frontal cortex after repeated MK-801 (1 mg/kg) treatment
for 1, 5, or 10 d. Immunoreactivities of p-Ser217/Ser221-
MEK1/2, p-Thr202/Tyr204-ERK1/2, p-Ser380-p90RSK, and
p-Ser133-CREB were increased vs. the vehicle controls in
the 5-d and 10-d treatment groups. The immunoreactivities
of MEK1/2, ERK1/2, p90RSK and CREB were similar to
those of the vehicle controls in the 1-d, 5-d, and 10-d
groups. (b) Quantification of immunoblot data by
densitometric analysis. The mean optical densities of
p-Ser217/Ser221-MEK1/2, p-Thr202/Tyr204-ERK1/2,
p-Ser380-p90RSK, and p-Ser133-CREB were significantly
increased vs. those of the vehicle controls in the 5-d and
10-d treatment groups. Quantification of immunoblot data














Figure 3. Increased immunostaining of p-Ser9-GSK-3b and
p-Thr202/Tyr204-ERK in rat prefrontal cortices after 10-d
treatment with MK-801 (1 mg/kg). Representative
fluorescence microscopic images taken from sections stained
for p-Ser9-GSK-3b [(a) and (b)] or p-Thr202/Tyr204-ERK1/2
[(e) and (f)], and counterstained with DAPI to label nuclei
[(c), (d), (g) and (h)]. All captured images were obtained
24 h after repeated daily treatment with MK-801 (1 mg/kg)
[(b), (d), (f) and (h)] or saline [(a), (c), (e) and (g)] for 10 d.
Phospho-Ser9-GSK-3b and phospho-Thr202/Tyr204-ERK1/2
stainings coincided with DAPI nuclear staining
(arrowheads). Phospho-Ser9-GSK-3b and phospho-Thr202/
Tyr204-ERK1/2 stainings were increased by increasing
MK-801 (arrowheads). Magnification bar=50 mm.
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2 mg/kg MK-801. Immunoreactivities of these phos-
phoproteins were all determined to have increased
significantly at 24 h after 5 d and 10 d repeated treat-
ments with 0.5 and 2 mg/kgMK-801 (all p<0 .05). The
findings with 0.5 and 2 mg/kg MK-801 showed same
pattern with those with 1 mg/kg MK-801. All optical
densities of these molecules’ immunoreactivities
with 0.5, 1, and 2 mg/kg MK-801 showed significant
increase compared to the vehicle controls value of
each treatment length group, whereas there were no
significant differences among immunoreactivities of
eachmolecule with 0.5, 1, and 2 mg/kgMK-801 within
each treatment length group. This finding demon-
strates that there was no dose-dependency with re-
peated treatments with MK-801 (0.5, 1, and 2 mg/kg)
(Figure 4).
In addition, immunoreactivities of HSP72, PARP,
and Bax were evaluated to investigate whether
neuronal damage occurred in response to repeated
treatments of MK-801. There were no significant
differences between the vehicle group and the
MK-801-treated group with regard to the HSP72,
PARP, and Bax immunoreactivity in the rat frontal
cortex, 24 h after 1, 5, and 10 daily repeated injections
with 1 and 2 mg/kg MK-801 (Figure 5).
Discussion
The most important finding of the present study is that
repeated treatments with 1 mg/kg MK-801 resulted
in the up-regulation of phosphorylation levels of the
Akt-GSK-3b and MEK-ERK-p90RSK pathways in the
rat frontal cortex. However, single MK-801 treatment
did not induce significant changes in these pathways.
CREB phosphorylation was also increased in the 5r
and 10r groups, and the same pattern of changes in
these molecules were found in the corresponding 0.5
and 2 mg/kg MK-801 groups. We also found that the
level of HSP-72 protein, a known marker of neuronal
death (Sharp et al., 1991), was not increased as a result
of these treatments.
It is interesting that the above alterations in the
Akt-GSK-3b and MEK-ERK-p90RSK pathways were
not observed after a single administration. Kyosseva
et al. (2001) reported that PCP increased MEK and
ERK1/2 phosphorylations in the cerebellum of rats
after 10-d and 20-d treatment, whereas 3 d of PCP
treatment did not result in any significant increases in
their phosphorylations. In contrast to these chronic
changes, we previously observed acute changes, at
1 h after a single injection of MK-801, on the phos-
phorylation levels of Akt-GSK-3b and MEK-ERK
pathways, and the responses of these pathways were
(a)
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Figure 4. Increased immunoreactivities of p-Ser473-Akt,
p-Ser9-GSK-3b, p-Ser217/Ser221-MEK1/2, p-Thr202/
Tyr204-ERK1/2, p-Ser380-p90RSK, and p-Ser133-CREB
in the rat frontal cortex induced by repeated daily treatment
with 0.5, 1, or 2 mg/kg MK-801. (a) Immunoblots of rat
frontal cortex after repeated exposure to MK-801 at the
indicated doses. The immunoreactivities of p-Ser473-Akt,
p-Ser9-GSK-3b, p-Ser217/Ser221-MEK1/2, p-Thr202/
Tyr204-ERK1/2, p-Ser380-p90RSK, and p-Ser133-CREB
were increased in the rat frontal cortex 24 h after 5-d
and 10-d daily treatment with 0.5, 1, and 2 mg/kg MK-801.
(b) Quantification of immunoblot data by densitometry.
The mean optical densities of p-Ser473-Akt, p-Ser9-GSK-3b,
p-Ser217/Ser221-MEK1/2, p-Thr202/Tyr204-ERK1/2,
p-Ser380-p90RSK, and p-Ser133-CREB were significantly
higher than those of the 2vehicle control after 5-d and
10-d MK-801 treatment. Quantification of immunoblot
data by densitometry performed as described in the
Figure 1 legend.
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different from each other (Ahn et al., 2005a,b). These
findings suggest that alterations in intracellular
signalling pathways induced by NMDA receptor
antagonists are dependent on the duration of exposure
and that this reflects an adaptive response to a chronic
NMDA receptor hypofunctional state.
Our finding that MK801, an NMDA receptor
antagonist, increases the phosphorylations of Akt and
ERK seems to contradict to reports that MK-801
reduces NMDA receptor-mediated ERK and Akt
phosphorylations in primary cortical cell cultures
(Chandler et al., 2001 ; Sutton and Chandler, 2002 ; Zhu
et al., 2005). This apparent discrepancy may be due to
compensatory changes induced by NMDA receptor
antagonist treatment in the brain, as MK-801 can
induce alterations in GABAergic, serotonergic, and
adrenergic neurotransmission systems (Farber, 2003 ;
Olney and Farber, 1995). Moreover, chronic treatments
with PCP can induce the synthesis of new synaptic
hyperfunctional NMDA receptors (Yu et al., 2002).
Therefore, the increased phosphorylations of Akt and
ERK may be related to a mechanism independent of
NMDA receptor antagonism by MK-801.
The PI3K-Akt and MEK-ERK pathways are
the principal pathways that contribute to neuronal
survival (Hetman and Gozdz, 2004 ; Zhu et al., 2005 ;
Zimmermann and Moelling, 1999). CREB exerts its
pro-survival effect by mediating Akt and ERK signal-
ling (Walton and Dragunow, 2000). The activation of
p90RSK is necessary for CREB to mediate ERK sig-
nalling (Frodin and Gammeltoft, 1999 ; Xing et al.,
1996), and we found that Ser380-p90RSK phosphory-
lation was increased after repeated MK-801 treatment
with a similar pattern with ERK1/2 and CREB phos-
phorylation. Of the many phosphorylation sites on
p90RSK, Ser380 phosphorylation is known to be im-
portant for activating the N-terminal kinase domain to
phosphorylate substrates of p90RSK, including CREB
(Dalby et al., 1998 ; Frodin and Gammeltoft, 1999).
Therefore, it appears that Ser133-CREB phosphoryl-
ation is mediated by MEK-ERK-p90RSK signalling in
response to repeated MK-801 treatment. In addition,
the apoptosis-inducing property of GSK-3b is in-
hibited by its phosphorylation at Ser9 by Akt (Cross
et al., 1995). Akt-GSK-3b signalling can also facilitate
CREB activation, but this activation is mediated by
phosphorylation at Ser129, not at Ser133 (Grimes and
Jope, 2001). Taken together, chronic MK-801 treatment
activates the Akt-GSK-3b and the MEK-ERK-p90RSK-
CREB pathways, which suggests that pro-survival and
anti-apoptotic activities of these signalling pathways
are enhanced in response to chronic exposure to
MK-801.
The immunoreactivities of HSP72, Bax, and PARP
remained unchanged in the rat frontal cortex, even
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Figure 5. No significant changes occurred in the
immunoreactivities of HSP72, Bax, or PARP in rat frontal
cortices after repeated MK-801 (1 and 2 mg/kg) treatment.
(a) Immunoblots of rat frontal cortex after repeated
treatments with MK-801 (1 and 2 mg/kg) for 1, 5, and 10 d.
Immunoreactivities of HSP72, Bax, and PARP were similar to
those of the vehicle controls in the 1-d, 5-d, and 10-d groups.
(b) Quantification of immunoblot data by densitometry. The
mean optical densities of HSP72, Bax, and PARP were similar
to those of the vehicle controls in the 5-d and 10-d groups.
Quantification of immunoblot data by densitometry
performed as described in the Figure 1 legend.
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known that HSP72 can be used to detect neuronal
injury (Carter et al., 2004 ; Sharp et al., 1991 ; Tomitaka
et al., 2000), and that HSP72 immunoreactivity (deter-
mined by Western blotting) may reflect neuronal
damage in brain tissue caused by NMDA receptor
antagonist treatment (Tomitaka et al., 2000). Bax
and PARP are constituents of the intrinsic caspase-
mediated cell-death pathway (Ferrer and Planas,
2003). Moreover, although it cannot completely pre-
clude the possibility of neuronal damage, it appears
that neuronal damage did not occur in the rat frontal
cortex in the present study, which may be related to
the activation of the pro-survival and anti-apoptotic
activities of signalling pathways. However, NMDA
receptor antagonists, such as MK-801, PCP, and
ketamine, have been reported to induce neuronal
damage in the corticolimbic regions of the rat brain
(Carter et al., 2004 ; Olney and Farber, 1995 ; Tomitaka
et al., 2000). In the present study, the absence of
observed changes in the immunoreactivities of HSP,
Bax, and PARP can be attributable to several factors.
First, male rats have been reported to be more resistant
to neuronal damage by MK-801 than female rats (Fix
et al., 1995), and the present experiments were con-
ducted on male rats. Second, we analysed the rat
frontal cortex. However, the regions reported to
show neuronal damage induced by NMDA receptor
antagonists are ; the posterior cingulate cortex, retro-
splenial cortex, and the limbic cortex (Carter et al.,
2004 ; Corso et al., 1997 ; Sharp et al., 1991 ; Tomitaka
et al., 2000). Thus, gender and brain regional differ-
ences could account for the observed discrepancy.
Recently, we reported that the behavioural changes
induced by MK-801 could be associated with the
phosphorylation levels of ERK and Akt pathways
in the rat frontal cortex (Ahn et al., 2005a,b). MEK
inhibitor (SL327), which blocks the ERK pathway in
the brain, has been reported to increase locomotion
(Einat et al., 2003). Moreover, repeated MK-801
administrations have been reported to induce behav-
ioural sensitization ; a phenomenon characterized by
the progressive enhancement of the drug’s ability to
stimulate locomotion and stereotypy, which are con-
sidered to be psychotomimetic behavioural changes
(Carey et al., 1995 ; Wedzony et al., 1993 ; Yang et al.,
2002). Although we did not measure behavioural
changes in this study, we did observe that the loco-
motor activity became more prominent and rapid
on increasing the number of MK-801 injections. Carey
et al. (1995) demonstrated that repetitive MK-801
treatments changed behavioural baselines, rather than
simply enhancing the behavioural responses elicited
by MK-801 treatment. This behavioural baseline
shift was considered to be adaptive change induced by
repetitive MK-801 treatment. Therefore, the acti-
vations of the ERK and Akt signalling pathways may
be the adaptive response in intracellular signal trans-
duction pathways related to the behavioural changes
induced by chronic exposure to MK-801.
In addition, NMDA receptor antagonists, such as,
MK-801, ketamine, and riluzole, have been suggested
to have antidepressant effects (Berman et al., 2000;
Papp and Moryl, 1994 ; Zarate et al., 2003), and the
ERK and GSK-3b signalling pathways have been
reported to be intracellular targets of antidepressant
action. Lithium is a well known GSK-3b inhibitor, and
other GSK-3b inhibitors have been shown to be able to
elicit rapid antidepressant-like effects (Gould et al.,
2004 ; Kaidanovich-Beilin et al., 2004). Fluoxetine was
reported to increase ERK1/2 expression in the frontal
cortex (Gould et al., 2004), but another study indicated
that fluoxetine inhibits ERK1/2 phosphorylation in the
hippocampus and frontal cortex (Fumagalli et al.,
2005). Moreover, imipramine reduced the patho-
physiologically induced dephosphorylation of GSK-3b
(Roh et al., 2005), or increased ERK1 phosphorylation
in the rat frontal cortex (Fumagalli et al., 2005). These
results suggest the drug-specific effects of ERK and
GSK-3b. The increased phosphorylations of ERK and
GSK-3b observed in the present study may also be
related to the antidepressant-like effect of MK-801, and
further studies are necessary to clarify this possible
relationship.
In summary, repeated treatment with MK-801
increased the activities of the MEK-ERK-p90RSK-
CREB and Akt-GSK-3b pathways in the rat frontal
cortex, without inducing significant neuronal damage.
This observed prolonged up-regulation of pro-
survival and anti-apoptotic activities indicates the
induction of adaptive changes in intracellular signal-
ling pathways to the chronic NMDA receptor hypo-
functional state, which could be related to the
schizophrenia-like effects of chronic MK-801 treat-
ment. Our findings can facilitate understanding with
regard to the action mechanism of NMDA receptor
antagonists as psychotomimetic agents.
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